In prostate cancer, the nuclear receptor suppresses the expression of cholesterol efflux genes under pro-tumor conditions while treatment with the RORγ antagonist abolished statin-induced, SREBP2-mediated feedback [35]. Here, SREBF2 is linked to neoplasm.